Latest News

RSV Infection Raises Risk for Acute Cardiovascular Events


 

FROM JAMA INTERNAL MEDICINE

More Testing Needed?

The results add to the evidence that RSV infections in older patients are associated with considerable morbidity and mortality. Unlike for COVID-19 and influenza, however, there is hardly any surveillance for RSV infections. RSV testing in hospitals is rare. Many doctors opt against testing for RSV because they are not aware of the importance of RSV as a pathogen in adults, but also because the diagnosis of RSV has no therapeutic consequences, wrote Dr. Woodruff and her colleagues.

Because there is no targeted therapy for an RSV infection, the detection of RSV can only be used as a marker for a risk for the development of an acute cardiovascular event, according to Dr. Baldus. Even considering the new study data, he emphasized, “Not every patient with a cardiovascular preexisting condition needs to be tested for RSV.”

The crucial factor is the clinical presentation. “If there is a clinical indication of pulmonary impairment (shortness of breath, tachypnea, subfebrile temperatures, or a diminished general condition) it would be desirable to perform an RSV test. This is especially true for patients requiring intensive care who need respiratory support,” said Dr. Baldus.

Benefits of Vaccination

The results highlight the basic epidemiology of potential cardiovascular complications of RSV infections, but before RSV vaccination became available, wrote Dr. Woodruff and her colleagues.

In 2023, the first RSV vaccine for adults aged 60 years and older was approved. “Here, a door to additional possibilities opens,” said Dr. Baldus. Although there are currently no official vaccination recommendations from Germany’s Standing Vaccination Commission, medical societies of oncologists and pulmonologists recommend vaccination against RSV. “Given the relevance of cardiovascular diseases for the prognosis of patients, but also for the occurrence of an acute cardiovascular event upon detection of RSV, the corresponding recommendation is expected to come,” said Dr. Baldus.

This story was translated from the Medscape German edition using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication. A version of this article first appeared on Medscape.com.

Pages

Recommended Reading

FDA Approves New Antibiotic for Uncomplicated UTIs
MDedge Internal Medicine
Vaccine Against Urinary Tract Infections in Development
MDedge Internal Medicine
New Contraindications to Coadministration of Atazanavir
MDedge Internal Medicine
In the Story of the Rubella Virus as a Source of Granulomas, the Plot Is Still Thickening
MDedge Internal Medicine
Mpox Presentation Compared in Different Racial, Ethnic Groups
MDedge Internal Medicine
New HIV Infections After Vampire Facials at Unlicensed Spa
MDedge Internal Medicine
Revamped Antibiotic May Treat Deadly Eye Infection
MDedge Internal Medicine
COVID Vaccines and New-Onset Seizures: New Data
MDedge Internal Medicine
New mRNA Vaccines in Development for Cancer and Infections
MDedge Internal Medicine
Do You Really Know a UTI When You See It?
MDedge Internal Medicine